Company Focus
Moderna
Latest Moderna News
Biotechnology
A staggering 800% increase in licensing agreement deal values for messenger ribonucleic acid (mRNA)-based innovator pharmaceuticals was recorded over 2019 to 2024 year-to-date (YTD), driven by the remarkable success of mRNA vaccines during the COVID-19 pandemic. 16 October 2024
Related News
Insights
Company Spotlight
A biopharma company developing products for the treatment of human disease, including immunology, metabolism, cardiology and ophthalmology.
Latest News & Features of interest to Moderna
Biotechnology
Last week’s research news included US biotech Avidity Biosciences releasing strong early-stage trial results for its Duchenne muscular dystrophy (DMD) candidate delpacibart zotadirsen (AOC 1044). On the regulatory front, the US Food and Drug Administration (FDA) approved Ascendis Pharma’s hypoparathyroidism drug Yorvipath. The FDA also granted approval for Gilead Sciences’ seladelpar, now trade-named Livdelzi, for the treatment of the rare liver disease PCB. Also of significant importance, the US Centers for Medicare and Medicaid Services (CMS) last week selected 10 drugs for the first cycle of negotiations for pricing under the Inflation Reduction Act (IRA). 18 August 2024
Pharmaceutical
Japanese drugmaker Ono Pharmaceutical (TYO: 4528) has announced that the US medicines regulator will consider vimseltinib under the Priority Review scheme. 16 August 2024
Pharmaceutical
Prolific Machines, a US biotech seeking to harness light to deliver unprecedented cellular control, has received a grant from the Bill and Melinda Gates Foundation to use its platform to produce more affordable monoclonal antibodies (mAbs). 15 August 2024
Pharmaceutical
US rare diseases focused biotech Quince Therapeutics today announced the online publication of data in The Lancet Neurology from its Phase III ATTeST (Ataxia-Telangiectasia Trial with the EryDex SysTem clinical trial evaluating the safety and efficacy of its lead asset, EryDex. 15 August 2024
Pharmaceutical
The World Health Organization (WHO) has declared the ongoing surge of mpox cases in the Democratic Republic of the Congo (DRC) and other African countries a public health emergency of global concern. 15 August 2024
Pharmaceutical
Th US Food and Drug Administration (FDA) has granted accelerated approval for Livdelzi (seladelpar) for the treatment of primary biliary cholangitis (PBC), a rare liver disease, said Gilead Sciences 15 August 2024
Biotechnology
Japanese drugmaker Chugai Pharmaceutical has filed a regulatory application with the Ministry of Health, Labor and Welfare (MHLW) for gene therapy delandistrogene moxeparvovec, for the treatment of Duchenne muscular dystrophy (DMD). 15 August 2024
Pharmaceutical
Pharmaceutical companies supplying products under the UK’s freshly-launched antibiotics subscription model must now certify compliance with a new industry standard. 14 August 2024
Pharmaceutical
Texas-based Lexicon Pharmaceuticals has announced that, following a strategic review of the company’s commercial and pipeline programs, it will refocus resources across the portfolio and cut jobs. 14 August 2024
Latest In Brief for Moderna
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Latest Relevant Ones To Watch News
California, USA-based biotech Nektar Therapeutics’ shares closed up more than 8% at $1.33 yesterday after it announced the sale of its only manufacturing facility. 5 November 2024
18 October 2024
24 September 2024
23 September 2024
16 September 2024
23 August 2024
22 August 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze